Copyright
©The Author(s) 2022.
World J Diabetes. Oct 15, 2022; 13(10): 802-808
Published online Oct 15, 2022. doi: 10.4239/wjd.v13.i10.802
Published online Oct 15, 2022. doi: 10.4239/wjd.v13.i10.802
Principles of the management | |
Blood glucose goals | Between 110 and 180 mg/dL in most patients. Less strict goals in patients at high risk for hypoglycemia |
Monitoring of blood glucose levels | At least 4 times daily. More frequently in selected patients (e.g., in the intensive care unit) |
Antidiabetic treatment | Insulin in most patients. Metformin and dipeptidyl peptidase-4 inhibitors might be considered. Other antidiabetic agents should be avoided |
Management of COVID-19 in hospitalized patients | Similar to non-diabetic patients. Patients receiving glucocorticoids or immunomodulatory agents should be carefully monitored for infections |
Management of COVID-19 in the outpatient setting | Patients with symptomatic COVID-19 are eligible for treatment with monoclonal antibodies, remdesivir, nirmatrelvir-ritonavir or molnupiravir |
- Citation: Mougakou E, Kyziroglou M, Tsankof A, Cholongitas E, Tziomalos K. Considerations for management of patients with diabetes mellitus and acute COVID-19. World J Diabetes 2022; 13(10): 802-808
- URL: https://www.wjgnet.com/1948-9358/full/v13/i10/802.htm
- DOI: https://dx.doi.org/10.4239/wjd.v13.i10.802